Illumina, Inc.

Illumina, Inc. is an American biotechnology company headquartered in San Diego, California. Incorporated in 1998, the company is a global leader in genomic sequencing and array-based technologies, developing, manufacturing, and marketing integrated systems for the analysis of genetic variation and biological function. Its mission is to improve human health by unlocking the power of the genome, with a vision for genomic information to be routinely used for prevention, diagnosis, and treatment.

Illumina's comprehensive portfolio includes DNA sequencing platforms such as NovaSeq X, NextSeq, MiSeq, and iSeq, along with reagents, software (e.g., DRAGEN, Illumina Connected Analytics), and services. These offerings serve a diverse customer base across academic and government research institutes, pharmaceutical and biotechnology companies, clinical and diagnostic laboratories, and applied markets including forensic science, consumer genomics, and agriculture. The company's technology enables applications in sequencing, genotyping, gene expression, and proteomics.

As of 2025, Illumina maintains a leading position in the genomics market, holding an estimated over 70% global market share in high-throughput sequencing. The company's market dominance is underpinned by continuous innovation, its proprietary sequencing-by-synthesis (SBS) technology, and a consumables-driven revenue model. Jacob Thaysen serves as the Chief Executive Officer. Recent strategic initiatives include the continued adoption of the NovaSeq X platform, launched in 2022 to reduce sequencing costs and expand high-throughput access, and a focus on accelerating revenue growth, expanding into multi-omics, and strengthening clinical diagnostics, particularly in oncology and rare diseases, following the divestiture of GRAIL in late 2024/early 2025.